Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.25Last Year’s EPS
-0.26Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -9.43%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Neutral
The earnings call detailed positive developments such as significant revenue growth in biopharma, strategic partnerships, and progress in clinical test volumes and reimbursement submissions. However, it also noted challenges like a decrease in quarterly revenue, lower gross margin expectations for 2025, and an expected decline in revenue from Natera. The sentiment is balanced, with significant achievements tempered by notable challenges.Company Guidance
During the Personalis Fourth Quarter 2024 Earnings Call, the company provided guidance for 2025, projecting total revenue in the range of $80 million to $90 million, despite an anticipated decline of about $20 million from Natera's business. They expect to grow their test volume by 30% to 40% each quarter until achieving reimbursement. In Q4 2024, they delivered 1,441 molecular tests, a 52% increase from the previous quarter, and reported a full year revenue of $84.6 million, up 15% from 2023. The biopharma segment grew 60% year-over-year, driven by clinical trial samples from Moderna. Cash usage for 2025 is projected at $75 million to $80 million, with a net loss of approximately $85 million, including $20 million of unreimbursed test costs. Gross margin is expected to be between 21% and 23%. The company aims to achieve Medicare reimbursement for at least two indications by the end of 2025.Full Year Revenue Growth
Personalis reported full year 2024 revenue of $84.6 million, a 15% increase over 2023, driven by a 60% year-over-year growth in biopharma.
Strong Partnership with Moderna
Extended a long-term agreement with Moderna to support ongoing clinical trials, expected to drive future revenue growth.
Significant Capital Raised
Raised approximately $115 million net in 2024 through strategic investments, including a $50 million investment from Merck.
Increased Clinical Test Volume
Personalis delivered 1,441 molecular tests in Q4, a 52% increase from the previous quarter.
Breast Cancer Submission for Medicare Reimbursement
Submitted for Medicare coverage for breast cancer testing, ahead of internal expectations.
Positive Physician Feedback
High retention of physicians using NeXT Personal, indicating satisfaction with the test.
---
PSNL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PSNL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $4.24 | $4.14 | -2.36% |
| Nov 06, 2024 | $5.58 | $4.32 | -22.58% |
| Aug 07, 2024 | $2.88 | $3.43 | +19.10% |
| May 08, 2024 | $1.56 | $1.65 | +5.77% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Personalis Inc (PSNL) report earnings?
Personalis Inc (PSNL) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Personalis Inc (PSNL) earnings time?
Personalis Inc (PSNL) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PSNL EPS forecast?
PSNL EPS forecast for the fiscal quarter 2025 (Q1) is -0.25.
---